Spiroindoline-Capped Selective HDAC6 Inhibitors: Design, 2 Synthesis, Structural Analysis, and Biological Evaluation
![Thumbnail](/xmlui/themes/Mirage2/images/white_rectangle.jpeg)
File Type:
PDFItem Type:
Journal ArticleDate:
2020Access:
openAccessCitation:
A. Prasanth Saraswati, Nicola Relitti, Margherita Brindisi, Jeremy D. Osko, Giulia Chemi, Stefano Federico, Alessandro Grillo, Simone Brogi, Niamh H. McCabe, Richard C. Turkington, Ola Ibrahim, Jeffrey O Sullivan, Stefania Lamponi, Magda Ghanim, Vincent P. Kelly, Daniela Zisterer, Rebecca Amet, Patricia Hannon, Francesca Vanni, Cristina Ulivieri, Daniel Herp, Federica Sarno, Antonella Di Costanzo, Fulvio Saccoccia, Giovina Ruberti, Manfred Jung, Lucia Altucci, Sandra Gemma, Stefania Butini, David W. Christianson, and Giuseppe Campiani, Spiroindoline-Capped Selective HDAC6 Inhibitors: Design, 2 Synthesis, Structural Analysis, and Biological Evaluation, ACS Medicinal Chemistry Letters, 2020Abstract:
Histone deacetylase inhibitors (HDACi) have emerged as promising therapeutics for the treatment of neurodegeneration, cancer, and rare disorders. Herein, we report the development of a series of spiroindoline-based HDAC6 isoform-selective inhibitors based on the X-ray crystal studies of the hit 6a. We identified compound 6j as the most potent and selective hHDAC6 inhibitor of the series. Biological investigation of compounds 6b, 6h, and 6j demonstrated their antiproliferative activity against several cancer cell lines. Western blotting studies indicated that they were able to increase tubulin acetylation, without significant variation in histone acetylation state, and induced PARP cleavage indicating their apoptotic potential at the molecular level. 6j induced HDAC6-dependent pSTAT3 inhibition.
Sponsor
Grant Number
European Union (EU)
No. 721906-TRACT
Author's Homepage:
http://people.tcd.ie/dzistrerhttp://people.tcd.ie/kellyvp
http://people.tcd.ie/josulli
Description:
PUBLISHEDType of material:
Journal ArticleCollections
Series/Report no:
ACS Medicinal Chemistry LettersAvailability:
Full text availableKeywords:
HDAC inhibitors, Spiroindoline, STAT3, Cancer therapy, HDAC6Subject (TCD):
CancerDOI:
https://dx.doi.org/10.1021/acsmedchemlett.0c00395Metadata
Show full item recordLicences: